	Urinary Micropeptides: Integrative In Silico Profiling and LC-MS/MS Analysis for Prostate Cancer Biomarker Discovery. Methods Mol Biol Ferreira R, Vitorino R. PMID: 41241913 [PubMed - indexed for MEDLINE]
	Intra- and inter-tumoural heterogeneity in von Hippel-Lindau disease-related renal cancer: a multimodal data study protocol. Eur Radiol Exp Rowe I, Colombo A, Corea F, Pisu F, Genova F, Uggé M, Ciaparrone C, Giangrasso A, Pipitone GB, Scotti GM, Larcher A, Colciago G, Morelli MJ, Lucianò R, Carrera P, Zeppa P, Caputo A, Bertini R, Montorsi F, Salonia A, Verze P, Palmisano A, Esposito A, Bernardi R, Capitanio U. PMID: 41241877 [PubMed - indexed for MEDLINE]
	Prognostic Role of Different T1 Substaging Systems on Recurrence and Progression in Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol Piccolini A, Moretto S, Fasulo V, Uleri A, Contieri R, Finocchiaro A, Cella L, Dagnino F, Avolio PP, Saita A, Lazzeri M, Casale P, Lughezzani G, Buffi NM, Hurle R, Colombo P, Valeri M, Paciotti M. PMID: 41241655 [PubMed - as supplied by publisher]
	Re: Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial. Eur Urol Bertolo R, Antonelli A. PMID: 41241556 [PubMed - as supplied by publisher]
	Urodynamic testing in refractory overactive bladder symptoms: the FUTURE study - Authors' reply. Lancet Abdel-Fattah M, Ward K, Dixon S, Chapple C, MacLennan G, Norrie J. PMID: 41241512 [PubMed - in process]
	Urodynamic testing in refractory overactive bladder symptoms: the FUTURE study. Lancet Kessler TM, Bachmann LM, Betschart C. PMID: 41241511 [PubMed - in process]
	Urodynamic testing in refractory overactive bladder symptoms: the FUTURE study. Lancet Serati M, Tarcan T, Peyronnet B, Solomon E, Finazzi-Agro E. PMID: 41241510 [PubMed - in process]
	Urodynamic testing in refractory overactive bladder symptoms: the FUTURE study. Lancet Tutolo M, Ammirati E, Montorsi F. PMID: 41241509 [PubMed - in process]
	The Renal Activity Index for Lupus: Validation for Prediction of Kidney Inflammation in Adult Patients with Lupus Nephritis. J Rheumatol O'Connor SK, Devarajan P, Liu J, Maldonado MA, Sproles A, Rose J, Thornton S, Chen C, Huang B, Brunner HI. PMID: 41241398 [PubMed - as supplied by publisher]
	siRNA-based nanocarriers for targeted therapy in prostate cancer: implications for male fertility preservation. Drug Discov Today Jangde KK, Shrama R, Mishra DK, Mishra PK. PMID: 41241375 [PubMed - as supplied by publisher]
	Exploratory randomized comparison of mirabegron and vibegron as first-line therapy for overactive bladder in elderly women. Urology Sato H, Otsuka S, Okumura Y, Tsukada S, Yoshida H. PMID: 41241296 [PubMed - as supplied by publisher]
	FAM20C and FAM20A in normal and ectopic mineralization: a focus on oro-renal syndromes. Matrix Biol Baker A, Tarrass MA, Chatziantoniou C, Kozyraki R. PMID: 41241263 [PubMed - as supplied by publisher]
	Metastatic prostate cancer: Clinical trials to watch. Med Gebrael G, Ostrowski M, Agarwal N. PMID: 41240901 [PubMed - indexed for MEDLINE]
	Immunofluorescent characterization of Klotho and FGF23 in clear cell renal cell carcinoma: A pilot study. Acta Histochem Racetin A, Kelam N, Glavina Durdov M, Vukojevi. PMID: 41240794 [PubMed - as supplied by publisher]
	Refining experimental design and translational relevance in tetramethylpyrazine studies on contrast-induced acute kidney injury. Int Urol Nephrol Riaz L, Khan M, Muqeet A. PMID: 41240248 [PubMed - as supplied by publisher]
	Concerns regarding matching and long-term risk assessment in living kidney donor outcome studies. Int Urol Nephrol Tariq B, Rizwan M, Mustafa M. PMID: 41240247 [PubMed - as supplied by publisher]
	Prophylactic laxative use for postoperative constipation in urological cancer: a real-world cohort study. World J Urol Wahafu W, Yang F, Yang T, Tan Z, Lan J, Chen T, Cao Z, Jiang M, Bao G, Pei Q, Zhou X, Guo X, Liu Y, Lu T, Tang Y, Liu C, Xu Y, Zhao H, Huo L, Zhang G, Xing N. PMID: 41240136 [PubMed - indexed for MEDLINE]
	Achieving sustainability in urology: a consensus study by the European association of urology (EAU) section office. World J Urol Tozsin A, Ahmed K, Soytürk S, Pradere B, Dasgupta P, Sönmez MG, Keller EX, Omar MI, Mallet R, Ayd, Gadzhiev N, Çak, Vasquez JL, Akgül B, Arslan E, S, Sanguedolce F, Roupret M, Musquera M, Ralph D, Colecchia M, Finazzi Agro E, Bettocchi C, Traxer O, Tunç L, Rassweiler J, Herrmann TRW, Knoll T, Güven S. PMID: 41240108 [PubMed - indexed for MEDLINE]
	The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 (68)Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient management. Eur J Nucl Med Mol Imaging Giesel FL, Koerber SA, Hadaschik B, Kiefer S, Schwarzenboeck S, Rahbar K, Derlin T, Grott CA, Heck M, Jilg C, Meyer PT, Ruf J, Schmidt K, Kotzerke J, la Fougère C, Reischl G, Virgolini I, Herrmann K, Burger IA, Lorenzini T, Werner M, Stenzinger A, Schwamborn K, Radtke JP, Hohenfellner M, Debus J, Weber WA, Haberkorn U, Kopka K, Eiber M, 68Ga-PSMA-11 DKTK trial contributors. PMID: 41240091 [PubMed - as supplied by publisher]
	Bladder region-specific analysis of the diagnostic performance of oral 5-aminolevulinic acid fluorescence cystoscopy in non-muscle-invasive bladder cancer. Jpn J Clin Oncol Ishikawa Y, Tanaka H, Kobayashi M, Fujiwara M, Nakamura Y, Fukuda S, Waseda Y, Yoshida S, Fujii Y. PMID: 41240010 [PubMed - as supplied by publisher]

Articles 1 - 20 / 456296

Page 1 of 22815



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy